Answers are grounded in this paper and cite their sources.
Abstract 2′-Fucosyllactose (2′-FL) exhibits prebiotic properties, but its ability to enhance probiotic efficacy in ulcerative colitis (UC) is incompletely understood. Here, we show that 2′-FL effectively enhances the protective effect of Bifidobacterium bifidum B-67 against DSS-induced colitis in mice. Combination therapy outperformed individual treatments, suppressing pro-inflammatory cytokines and restoring mucosal integrity. Mechanistically, 2′-FL remodeled the gut microbiota, enriched butyrate-producing Lachnospira, promoted SCFA production, and upregulated epithelial adhesion molecules HAS1 and GPC-1, which are associated with enhanced Lachnospira adhesion. In vitro coculture further indicated that B. bifidum B-67 acts as the primary degrader of 2′-FL and supports Lachnospira growth, suggesting a cross-feeding effect. Untargeted metabolomics revealed distinct metabolic alterations, including in bile acid-related pathways, associated with the combination intervention. These findings indicate that 2′-FL potentiates B. bifidum via both metabolic cross-feeding and enhanced bacterial retention, supporting this synbiotic combination as a promising strategy for UC intervention.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: